iCAD Unveils ProFound AI™ for Digital Breast Tomosynthesis at RSNA 2018
Clinical results presented demonstrate outstanding outcomes with world-class
artificial intelligence technology
NASHUA, N.H. and CHICAGO (Booth #3911 and #8161) – (Nov. 26, 2018) – iCAD,
Inc. (NASDAQ: ICAD), a global medical technology leader providing
innovative cancer detection and therapy solutions, today announced the global
brand identity for its latest artificial intelligence software solution for digital breast
tomosynthesis (DBT), ProFound AI™. This high-performance, deep-learning
technology revolutionizes the way radiologists interpret and manage DBT data. Study
results presented during an oral presentation at the Radiological Society of
North America (RSNA) annual meeting at McCormick Place in Chicago showed that
radiologists’ concurrent use of ProFound
AI for DBT increased detection of breast cancer, while also decreasing
false positives, unnecessary recalls and reading time. The algorithm is the
world’s first solution to achieve these unprecedented results.
“As AI continues to transform the healthcare landscape, we are pleased
to present the unrivaled clinical results our technology offers to radiologists,
their facilities, and their patients at this year’s RSNA meeting,” said Stacey
Stevens, Executive Vice President and Chief Strategy and Commercial Officer at
iCAD. “Powered by more than 12,000 patient cases, our solution is proven through
a rigorous clinical study to help clinicians find more cancer, decrease false
positives, reduce recalls and reading time. These results are truly profound.”
In the presentation, Emily F. Conant, MD, Principal Investigator, Professor
and Chief, Division of Breast Imaging, Vice Chair of Faculty Development,
Department of Radiology, Hospital at the University of Pennsylvania in
Philadelphia, detailed results of the retrospective, fully-crossed,
multi-reader, multi-case study that compared the performance of 24 radiologists
reading 260 DBT cases both with and without ProFound AI between two separate
reading sessions. The findings showed that the concurrent use of ProFound AI by
radiologist study participants improved cancer detection rates with an average increase
in sensitivity of 8.0 percent. The false positive rate decreased with an
average improvement in specificity of 6.9 percent. The solution also delivered significant
workflow benefits by reducing reading time by 52.7 percent on average.
“To increase both sensitivity and specificity while also substantially reducing
reading time is an impressive outcome,” said Emily F. Conant, MD. “These
findings underscore the significant clinical value of incorporating deep-learning
technology in the interpretation of DBT studies. Including AI in DBT reading offers
physicians confidence without compromise, resulting in better quality of care
for patients.”
In addition to the new data released at the scientific assembly, iCAD
will also present “How AI Can Improve Diagnostic Performance and Reduce Reading
Time in Breast Tomosynthesis,” led by Senthil Periaswamy, PhD, Vice President
of Research, iCAD. The session held on Tuesday at 1:30pm CT will focus on how ProFound
AI improves breast cancer detection, reduces recalls and improves reading
efficiency for DBT. For more information, including experiential learning
sessions about the solution, please visit iCAD’s booth #3911 in the South Hall
or in the new Machine Learning Showcase located in the North Hall, booth #8161.
iCAD’s
ProFound AI is a high-performance, deep-learning, cancer detection and workflow
solution for DBT delivering critical benefits to radiologists, their
facilities, and their patients. The new technology is trained to detect malignant
soft-tissue densities and calcifications and also provides radiologists with
scoring information representing the likelihood that a detection or case is
malignant based on the large dataset of clinical images used to train the
algorithm. The
solution is currently available for use with leading DBT systems in Europe and
Canada. It is pending clearance by the United States Food and Drug
Administration (FDA). For more information, visit www.icadmed.com.
About
iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global
medical technology leader providing innovative cancer detection and therapy
solutions. For more information, visit www.icadmed.com.
“Safe
Harbor” Statement under the Private Securities Litigation Reform Act of
1995
Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements involve a number
of known and unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of the Company to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Such factors include, but are not
limited to the Company’s ability to defend itself in litigation matters, to
achieve business and strategic objectives, the risks of uncertainty of patent
protection, the impact of supply and manufacturing constraints or difficulties,
uncertainty of future sales levels, protection of patents and other proprietary
rights, product market acceptance, possible technological obsolescence of
products, increased competition, litigation and/or government regulation,
changes in Medicare or other reimbursement policies, risks relating to our
existing and future debt obligations, competitive factors, the effects of a
decline in the economy or markets served by the Company; and other risks
detailed in the Company’s filings with the Securities and Exchange Commission.
The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”,
“consider”, “project”, “estimate”, “will”, “continue”, “anticipate”, “likely”,
“seek”, and similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking statements,
which speak only as of the date the statement was made. The Company is under no
obligation to provide any updates to any information contained in this release.
For additional disclosure regarding these and other risks faced by iCAD, please
see the disclosure contained in our public filings with the Securities and
Exchange Commission, including the 10-K for the year ended December 31, 2017,
available on the Investors section of our website at https://www.icadmed.com and
on the SEC’s website at http://www.sec.gov.
Contact:
Media Inquiries:
ARPR, on behalf of iCAD, Inc.
Paul Barren, (855) 300-8209
Investor Relations:
LifeSci Advisors, on behalf of iCAD, Inc.
Jeremy Feffer, (212) 915-2568